Menu
Recruiting NCT06172569

Spartan Stem, World Cup and World Liner Post Market Clinical Follow-up Study

Observational Hip Replacement

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Spartan Stem, World Acetabular Cup and World Liner.
Who it may be relevant to
Registry conditions: Hip Replacement. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

The aim of the study is to monitor the performance of the Signature Orthopaedics Spartan Stem, World Acetabular Cup and World Liner as a post-market vigilance and continuous improvement efforts.

Detailed description

The objective of this PMCF Study is to collect data confirming safety, performance and clinical benefits of the Spartan Stem, World Acetabular Cup and the World Liner when used for primary total hip arthroplasty at 2-years follow-up.

The study includes pre-operative, operative, discharge, 1 year post-operative evaluations, where data concerning the performance and safety of the device are gathered.

The revision rate of the components will be monitored as the primary objective, along with pre and post operative measurement of the Oxford Hip Score (OHS), patient-reported outcome measure (PROM) to quantify patient satisfaction.

Radiography analysis will be done to monitor bony response to the implant and qualify the effectiveness of the cementless fixation.

Interventions

  • Device Spartan Stem, World Acetabular Cup and World Liner
    The Spartan Stem is a wedge-shaped fit and fill design stem with Titanium Plasma Spray(TPS) and Hydroxyapatite (HA) coating. The World Acetabular cup is Porous coated and mated with cross-linked polyethylene World Liner

Primary outcome measures

  • Spartan Stem, World Acetabular Cup and World Liner Survival Rate [Time frame: up to 2 years]
Secondary outcome measures (1)
  • Oxford Hip Score (OHS) [Time frame: up to 2 years]

Eligibility criteria

Inclusion criteria

  • patient requires unilateral primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g., osteoarthritis, traumatic arthritis, avascular necrosis, dysplasia/DDH)
  • patient must be a candidate for use of the products studied, as determined jointly by the surgeon and patient.
  • male and non-pregnant female patients aged 18-75
  • patients who understand the conditions of the clinical evaluation and are willing to participate for the length of the prescribed follow-up.

Exclusion criteria

  • patient has active infection or sepsis(treated or untreated) enough to compromise implant stability or postoperative recovery
  • patient is a female of child-bearing age and not taking and not taking contraceptive pills
  • patient has inadequate bone stock to support the device (e.g. severe osteopenia, family history of severe osteoporosis or osteopenia)
  • patient has a known or suspected metal sensitivity
  • patient is immuno-suppressed with disease such as AIDS or is receiving high dose of cortico-steroids.
  • patient has an emotional or neurological condition that would pre-empt their ability or unwillingness to participate in the clinical evaluation including mental illness, mental retardation or drug abuse
  • patient is severely overweight with a BMI>40.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

United States · 1 center
  • Cleveland Clinic — Cleveland

Identifiers

NCT: NCT06172569 · 111-440-100

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗